Just add water! The synthesis of a number of tricomponent glycopeptide cancer-vaccine candidates is described. These vaccines contain a tumor-associated peptide or glycopeptide antigen covalently linked to a universal T-cell helper peptide and an immunoadjuvant. These vaccines spontaneously self-assembled in aqueous media to form stable nanoparticles and 
Introduction
Training the immune system to recognize and eliminate tumor cells through vaccination strategies is considered an extremely promising approach for the safe control of metastases in cancer patients.
[1] An important feature of an effective vaccine-induced immune response is that it is cancer specific, a task made difficult by the ubiquitous presentation of antigens on both normal and cancer cells. The key to vaccine design has therefore centered on exploiting differences in expression levels and/or specific modifications of proteins found on cancer cells to mount a selective immunological attack against tumors. Mucin 1 (MUC1) is a transmembrane glycoprotein expressed on the apical surface of a range of epithelial cells and has a specific tumor-associated profile. [2] The extracellular section of MUC1, which extends almost 200^^nm above the cell surface, contains a VNTR domain comprised of 20 amino acid residues (GVTSAPDTRPAPGSTAPPAH) with five sites for potential O-glycosylation.
[2a]
Although present on normal cells, MUC1 has been shown to be highly overexpressed in over 90^% of solid and nonsolid tumors, including carcinomas of the breast, colon, pancreas, prostate, ovary, rectum, and stomach. [2] Another notable feature of MUC1 is the aberrant glycosylation of the MUC1 VNTR domain on tumorogenic cells. [3] This alteration in the 3 3 glycosylation profile arises from the dysregulation of glycosyltransferase enzymes that serve to elongate O-glycan chains on normal cells. [4] This behavior leads to the presentation of highly truncated tumor-associated carbohydrate antigens (TACAs) on the surface of numerous epithelial cancer cells, including the well-studied TN and T antigens and their sialylated derivatives (sialyl TN and sialyl T; Figure^^1<figr1>) . [2--4] These TACAs serve as crucial biomarkers for disease progression and have emerged as promising targets for the development of antigen-specific cancer vaccines. [2a,^5] However, immunization using TACAs alone has failed to provide adequate immune protection due to the fact that they are selfantigens and are tolerated by the immune system. A key challenge underpinning the successful development of a MUC1-based vaccine is the need to break immune self-tolerance to provide a durable cellular and humoral immune response, characterized by the induction of immunoglobulin G (IgG) antibodies and tumor-specific cytotoxic T-lymphocytes (CTLs) against TACAs and/or MUC1 (glyco)peptide epitopes.
[5]
One approach is aimed at enhancing the immune response and has focused on the conjugation of TACAs and tumor-associated MUC1 (glyco)peptide fragments to immunogenic carrier proteins, such as keyhole limpet hemocyanin, bovine serum albumin, and tetanus toxoid. [5,^6] More recently, we and others have reported the synthesis and immunological evaluation of other fully synthetic tricomponent vaccines based around this design concept.
[9]
In a recent study, we have shown that tricomponent (glyco)peptide vaccines that incorporate the full-length MUC1 VNTR, an immunogenic peptide fragment of the tetanus toxoid protein as a T-cell helper epitope, and the immunoadjuvant Pam3CysSer could elicit strong antibody responses in murine models.
[9a] Importantly, these vaccines were completely self-adjuvanting and did not require supplementation with commonly employed immune stimulators such as alum or the complete Freund adjuvant.
We were interested in extending this concept by designing self-adjuvanting vaccines that possess a universal T-cell helper epitope, which, unlike our previous constructs, would be directly translatable to human studies should they prove to be efficacious in an animal model.
To this end, we now report the efficient synthesis and immunological evaluation of fully selfadjuvanting tricomponent conjugate vaccine candidates 1--3 that possess a MUC1 peptide or glycopeptide antigen, an immunoadjuvant, and a synthetically-derived universal T-cell helper epitope (Figure^^2<figr2>). We also report the spontaneous self-assembly of these synthetic vaccines in aqueous media to form discrete nanoparticles.
Results and Discussion
<+>Vaccine design: The target vaccines 1--3 were designed to incorporate the necessary structural features to elicit robust cellular and/or humoral immunity (Figure^^1<xfigr1>). Specifically, 1--3 were designed to comprise a complete copy of the 20-amino-acid VNTR domain of MUC1 bearing either no glycosylation or five copies of the TN 5 5 and T antigens as the vaccine antigen, covalently tethered to the PADRE T-cell helper peptide epitope, and Pam3CysSer as a built-in immunoadjuvant. Installation of an immunogenically silent triethylene glycolate spacer unit between each vaccine component was proposed to minimize conformational distortion and to allow for optimal display of each recognition element to the immune system, as has been reported previously. [9b,^10] We chose to incorporate MUC1 glycopeptides with saturated occupancy with TACAs because this architecture is known to be present on tumor-associated MUC1.
[11] Despite a report that suggests that antigen-presenting cells (APCs) have an impaired ability to process peptides bearing clustered presentation of TACAs, [12] vaccines that incorporate these features have been shown to elicit high IgG antibody titres when conjugated to a foreign carrier protein or an external adjuvant. [13] The inclusion of the full-length, per-glycosylated VNTR into the vaccine constructs enables simultaneous presentation of multiple immunogenic epitopes on major histocompatibility complex (MHC) molecules, including the antibody immunodominant sequences RPAPGS and PDTRP and the per-glycosylated HLA-A2 binding peptide SAPDTRPAPG (which includes the H-2Kb binding epitope SAPDTRPA).
[14]
The PADRE T-cell helper peptide component was incorporated to facilitate the induction of a robust protective immune response against the MUC1 (glyco)peptide antigens.
This synthetically engineered T-cell helper epitope was chosen because it has been demonstrated to elicit effective T-cell responses and bind multiple human leukocyte antigen (HLA) binding molecules, thereby overcoming strong HLA polymorphism within the human population. [15] The inclusion of this T-cell helper peptide would therefore enable promising candidates to be directly translated from models in vivo to human studies. Pam3CysSer is a well-studied agonist of toll-like receptor-1--toll-like receptor-2 (TLR1--TLR2) heterodimers, which activates nuclear factor κB (NF-κB) and stimulates the secretion of proinflammatory cytokines through signaling by the myeloid differentiation primary response gene 88 (MYD88). [16] This behavior leads to the maturation of dendritic cells and antibody-producing plasma cells upon vaccination.
[16b] It should be noted that traditionally Pam3CysSer(Lys)4 is utilized as an immunoadjuvant, whereby the four lysine (Lys) residues are presumably present to aid in the aqueous solubility of the final constructs. [8a,c] We chose to omit these Lys 6 6 residues from our vaccine candidates to provide a molecule with defined hydrophobic and hydrophilic moieties to facilitate self-assembly in solution.
<+>Synthesis: The synthesis of 1--3 was proposed to proceed through the conjugation of the three vaccine components by using our recently reported pentafluorophenyl estermediated fragment condensation strategy. building blocks 10--13 (synthesized as reported previously) [18] were coupled in slight excess (1.2^^equiv) with HATU (1.2^^equiv) as the coupling reagent and DIPEA (2.4^^equiv) in DMF. Following elongation, the peptides were deprotected and cleaved from the resin by using an acidic cocktail of TFA/triisopropylsilane/water (90:5:5, v/v/v). The O-acetate protecting groups on the glycan units were subsequently removed by treatment with hydrazine hydrate. [19] The target MUC1 (glyco)peptides 4--6 were purified by reversed-phase HPLC and isolated in 14--45^% yield, based on the original resin loading.
Synthesis of the N-Fmoc-and side-chain-protected PADRE peptide was achieved by using linear Fmoc SPPS and employing 2-chlorotrityl chloride resin 14 preloaded with an and Thr-8 positions to prevent aggregation during peptide elongation as described by Delmas and co-workers previously. [20] Following cleavage from the resin by using 30^% HFIP in dichloromethane, the side-chain-protected peptide acid was isolated (in a purity of approximately 85^% by analytical HPLC). The crude protected peptide acid was treated with an excess of pentafluorophenyl trifluoroacetate and pyridine, [21] thus resulting in a smooth conversion into the corresponding pentafluorophenyl ester within 4^^hours (as judged by LC-MS and TLC analysis). The C-terminal pentafluorophenyl ester 7 was isolated in 17^% yield (based on the resin loading of 14) following purification by preparative normal-phase HPLC.
The protected Pam3CysSer lipodipeptide fragment 8 was also assembled by using linear Fmoc SPPS from the resin-bound intermediate 14 (see Scheme^^2<xschr2> and the Supporting Information).
[9a] Following elongation, the side-chain-protected lipopeptide 8 was cleaved from the resin by using 30^% HFIP in dichloromethane and isolated in near quantitative yield (95^%) following purification by flash chromatography on silica gel (see the Supporting Information for the synthetic details).
With the fully unprotected MUC1 (glyco)peptides 4--6, peptide pentafluorophenyl ester fragment 7, and lipopeptide 8 in hand, we sought to assemble the proposed tricomponent vaccines 1--3 by a convergent fragment-condensation approach (Scheme^^3<schr3>).
Unprotected MUC1 (glyco)peptides 4--6 were treated with PADRE pentafluorophenyl ester 7 in the presence of HOBt and DIPEA to afford the desired conjugate. These reactions were complete within 16^^hours (as judged by LC-MS), at which point the Fmoc carbamate was <+>Self-assembly: We envisaged that the unique structural features within the proposed vaccines, specifically a hydrophilic MUC1 peptide or glycopeptide antigen and a hydrophobic Pam3Cys moiety at opposing ends of the construct, would lead to amphiphilic molecules that may self-assemble in aqueous media into micelles or particles, thus providing access to discretely sized nanoparticle vaccines. Such vaccines have been shown to possess numerous advantages over conventional approaches, including improved stability in vivo, stabilization of the native peptide antigen conformation, [22] and multivalent antigen presentation, which provides enhanced B-cell responses owing to the clustering of the antigens on the particle surface.
[23] Furthermore, several self-assembled vaccines have demonstrated adjuvanting activity in the absence of any other immunostimulatory agents.
[24]
Nanoparticle vaccines are also powerful vehicles for vaccine delivery because they have been shown to display improved delivery to the lymph nodes and enhanced uptake by antigenpresenting cells (APCs). [26]
To assess if the particles would dissociate upon dilution (which would occur upon vaccination), we tested the stability of the aggregations by further diluting the vaccines in water. The particle sizes (as measured by DLS) were independent of concentration (1--0.05^^mg^mL <M->1 ), and the surface tension was measured to be that of pure water in all the cases. If the aggregates were dynamic micelles, we would expect the surface tension to be measurably lower than that of water for any sample that contains a significant proportion of assembled aggregates. We observed both aggregates by DLS and no change in surface tension from that of water at low concentrations was found, thus suggesting that the aggregates are frozen rather than dynamic micelles in aqueous solution and are likely to remain in the assembled form down to very low concentrations in vivo. This spontaneous self-assembly of
1--3 in aqueous solution to form nanoparticles of discrete sizes may well have implications
for stimulation and increased uptake of the vaccines by antigen-presenting cells and, as such, may contribute (together with activation through TLR1--TLR2 pathways) to the immunostimulatory properties of the vaccines.
[25b]
<+>Immunology: To evaluate the immunogenicity of tricomponent vaccines 1--3, C57BL/6 mice (n=4) were injected intradermally with 20^^μg of each vaccine (diluted in 10 vol.^% DMSO in phosphate-buffered saline (PBS)) three times on days 0, 10, and 17. Two weeks following the final immunization, serum-antibody levels were assessed by enzymelinked immunosorbent assay (ELISA) to identify vaccine-induced antibodies. For the determination of antibody titres, ELISA plates were coated with unconjugated versions of MUC1 (glyco)peptides 4--6 dissolved in carbonate/bicarbonate coating buffer (0.05^M NaHCO3/Na2CO3; pH^^9.6). Mouse sera (serially diluted in 0.5^% skim milk/PBS) was added to the plates to assess antibody levels against each corresponding (glyco)peptide antigen (see the Supporting Information). Robust antibody responses were observed for all the vaccines, in the absence of an external adjuvant, with the total IgG endpoint titres ranging from 1775 to 8400 (Figure^^4<figr4>). These antibodies were selective for the MUC1 10 peptide and glycopeptide antigens to which they were raised, as determined by crossreactivity ELISA assays (see the Supporting Information).
The breakdown in antibody isotypes was also determined for 1--3 for each animal by using specific secondary antibodies (Figure^^5^A<figr5>--C) . In comparison to the IgG total titres, relatively low levels of IgM antibodies were produced by the vaccines following the third immunization, thus suggesting effective antibody-class switching, an important factor for the production of an effective vaccine. A predominance toward the type-2 helper T-cell (Th2) phenotype was observed, with higher levels of circulating IgG1 antibodies detected relative to the Th1 indicator, that is, IgG2c, in C57BL/6 mice.
[27] Interestingly, high levels of IgG3 antibodies were also induced by all the vaccines. The principal specificity of this isotype is against carbohydrates, and it elicits a powerful effector function in early immune responses. also bind to MUC1 epitopes on B16.MUC1 cells; however, the binding was weaker than that observed toward MCF7 cells.
Conclusion
We have successfully synthesized a small library of tricomponent self-adjuvanting MUC1 (glyco)peptide vaccines by using a convergent-fragment condensation approach.
These vaccines, which possessed a MUC1 (glyco)peptide antigen, PADRE as a universal Tcell helper epitope and Pam3CysSer as an immunoadjuvant, were shown to self-assemble in aqueous media, thus providing isotropic particles of uniform size (average size=20^^nm), as confirmed by DLS and TEM imaging. All three vaccines induced strong humoral responses in murine models. These antibodies were selective for the antigen to which they were raised and analysis of antibody isotypes showed significant levels of IgG1 antibodies suggestive of a Th2 skewed response. Sera antibodies could also recognize and bind to two types of tumor cell that overexpress MUC1 on their surface. The results from this study provide significant insight into the design features required for the effective self-assembly of molecularly defined vaccines and for the generation of strong antibody responses without the need for additional adjuvants. Future work in our laboratories will involve the investigation of the self-assembly and immunological activity of other multicomponent self-adjuvanting vaccines, the results of which will be reported in due course.
Experimental Section
Solid-phase synthesis of peptide pentafluorophenyl ester (7; scale: 100^^μmol):
Resin loading: 2-Chlorotrityl chloride resin (Novabiochem) was swollen in dry dichloromethane (5^^mL) for 30^^min. A solution of Fmoc-PEG(9^^atoms)-OH (77^^mg, 200^^μmol, 2.0^^equiv) and DIPEA (70^^μL, 0.4^^mmol) in DMF/dichloromethane (1:1 v/v, 1^^mL) was added, and the resin shaken at room temperature for 16^^h. The resin was filtered and washed with DMF (5×3^^mL), dichloromethane (5×3^^mL), and DMF (5×3^^mL). The resin was treated with a solution of dichloromethane/CH3OH/DIPEA (17:1:1 v/v/v, 3^^mL) for 1^^h, filtered, and washed with DMF (5×3^^mL), dichloromethane (5×3^^mL), and DMF (5×3^^mL).
Fmoc deprotection:
The preloaded 2-chlorotrityl chloride resin (100^^μmol) was initially swollen in DMF (5^^mL) for 30^^min. A solution of piperidine/DMF (1:9 v/v, 5^^mL) was added to the resin, which was shaken for 3^^min and the procedure was repeated. The resin was subsequently washed with DMF (5×3^^mL), dichloromethane (5×3^^mL), and DMF (5×3^^mL).
Amino acid coupling:
A solution of the protected amino acid (400^^μmol, 4.0^^equiv), PyBOP (208^^mg, 400^μmol, 4.0^^equiv), and NMM (88^^μL, 800^^μmol, 4.0^^equiv) in DMF (1^^mL) was added to the resin and shaken. After 1^^h, the resin was washed with DMF (5×3^^mL), dichloromethane (5×3^^mL), and DMF (5×3^^mL). Coupling of Trp-7 and Thr-8 was achieved by adding a solution of Fmoc-Trp(Boc)-Thr(ψ Me,Me pro)-OH (150 μmol, 1.5^^equiv), HATU (150^^μmol, 1.5^^equiv), and DIPEA (300^^μmol, 3.0^^equiv) in DMF (1^^mL) to the resin, which was shaken for 16^^h. The resin was washed as described above.
Resin cleavage: The resin was washed thoroughly with dichloromethane (10×3^^mL) and treated with a solution of hexafluoroisopropanol in dichloromethane (30^^vol.^%) and shaken for 2^^h at room temperature. The resin was filtered and washed with dichloromethane (5×2^^mL), and the filtrate and washings evaporated to dryness. The residue was coevaporated with toluene (3×5^^mL) and dried under high vacuum overnight.
Activation:
The crude peptide acid was dissolved in dry DMF (0.1^M) under argon. Pyridine (5.0^^equiv) was added followed by the dropwise addition of pentafluorophenyl trifluoroacetate (5.0^^equiv). The reaction was stirred at room temperature for 4^^h and the solvent was removed in vacuo. The crude residue was purified by preparative, normal-phase HPLC to afford pentafluorophenyl ester 7 following lyophilization from tert-butanol/acetonitrile (1:1 v/v).
7:
Yield: 17^% (based on resin loading of 100^^μmol ) and 1-hydroxybenzotriazole (10^^μL, 2.4^^μmol, 1.2^^equiv) in DMF (24^^mg^mL <M->1 ) were added to a solution of (glyco)peptides 4--6 (2.0^^μmol) in dry DMF (80^^μL). This solution was added to the peptide pentafluorophenyl ester 13 13 (4.0^^μmol), and the reaction mixture was gently agitated at room temperature for 16^^h. Piperidine (20^^μL) was added to the reaction mixture, which was agitated for a further 30^^min at room temperature. The solvent was removed in vacuo and the residue was purified by preparative reversephase HPLC followed by lyophilization to afford the desired (glyco)peptides 15--17. ) diluted in carbonate/bicarbonate coating buffer (0.05^M, pH^^9.6) and incubated overnight at 4^°C. The plates were washed with PBS 0.05^% Tween (PBST) and blocked with PBST containing 5^% skim milk for 2^^h at 37^°C. The mouse serum diluted in PBST and 5^% skim milk was added to the plates at appropriate dilutions and incubated for 90^^min at 37^°C. The plates were washed and incubated with 0.5^^μg^mL <M->1 horseradish peroxidase conjugated goat antimouse IgG Ab for 2^^h at 37^°C. The serum antibodies were detected by developing with 3,3',5,5'-tetramethylbenzidine (TMB) substrate solution (Sigma--Aldrich) for 20^^min, reactions were stopped using 1^M HCl, and the absorbance was measured at <Gl>=450^^nm on an ELISA plate reader. The endpoint titre was defined as the highest dilution of serum at which a positive antibody response is detectable, and a positive response was calculated as the mean absorbance of naïve serum with two standard deviations. Figure^^3 TEM images of vaccine 1 assembled in water deposited on a)^^an unstained carbon-coated grid and b)^^a graphene oxide grid.
Figure^^4 Anti-MUC1 IgG total reciprocal antibody titres elicited by self-adjuvanting vaccines 1--3 after three immunizations.
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Figure^^5 Anti-MUC1 IgG isotype reciprocal antibody titres elicited by self-adjuvanting vaccines A)^^1, B)^^2, and C)^^3 after three immunizations
